Drug Delivery Spin-Off Adds OTC
This article was originally published in Start Up
Vectura, focused on pulmonary drug delivery, has created a spin off which assembles the oral and dermal technologies it had already de-prioritized, with two enabling technologies from Unilever. PharmaKodex Ltd. will develop OTC drugs as a fast route to market, followed by Rx products using the same technologies.
You may also be interested in...
Europe's summertime flurry of private biotech sell-offs points to growing pragmatism among management and VCs, and still-poor valuations on the public markets. Firms which haven't already considered the trade sale opportunity should do so--even early-stage, pre-product platform groups.
COVID-19 has triggered a dramatic shift toward virtual consultations and telemedicine, encouraged by more relaxed regulations and payer support.
As the global shut-down caused by the coronavirus pandemic continues, sponsors are rushing to adapt clinical trials that can move to partial or completely remote monitoring, allowing patients to remain in their homes but continue to participate in studies. And the outbreak may have another silver lining for the biopharma industry, a chance to rebuild its reputation.